News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • NVIDIA shares rose after KeyBanc raised its target and institutional investors added positions ahead of Q1 FY2027 earnings.
  • U.S. stocks closed lower as longer-dated Treasury yields climbed, cooling risk appetite ahead of heavy corporate earnings this week.
  • Ford stock jumped after Ford Energy secured a five-year EDF contract to supply up to 20 GWh of battery storage and expanded European EV plans.
  • Regeneron shares plunged after its Phase 3 melanoma trial failed to meet the primary endpoint, prompting analyst downgrades and valuation cuts.
  • Hostilities continued across southern Lebanon and northern Israel despite a 45-day truce extension, sustaining regional geopolitical risk and civilian casualties.
  • President Trump voluntarily dismissed his $10 billion lawsuit against the IRS, leaving settlement terms and motives unclear.

Latest Articles

Coherent Director Executes $856,550 Share Sale Amid Company Momentum

Coherent Director Executes $856,550 Share Sale Amid Company Momentum

Stephen A. Skaggs, a director at Coherent Corp, disposed of 3,523 shares on March 9, 2026, through a pre-arranged Rule 10b5-1 plan, generating roughly $856,550. The transaction occurred at a weighted average price of $243.1309 per share, with sale prices between $237.90 and $250.00. After the sale Skaggs retains 16,864 shares. Coherent's stock has …

Aquestive Therapeutics CPO Executes Stock Sale to Satisfy Tax Withholding; Retains Substantial Equity Stake

Aquestive Therapeutics CPO Executes Stock Sale to Satisfy Tax Withholding; Retains Substantial Equity Stake

Summary: Aquestive Therapeutics Chief People Officer Peter E. Boyd completed a mandated sale of 29,814 common shares on March 10, 2026, while also taking delivery of restricted stock and stock options that vest over three years. The sale, executed under the companys equity incentive plan to meet tax withholding obligations, generated $124,413. Fol…

Lower Chamber Rejects Sheinbaum’s Electoral Overhaul as Coalition Frays

Lower Chamber Rejects Sheinbaum’s Electoral Overhaul as Coalition Frays

An electoral reform put forward by President Claudia Sheinbaum failed to obtain the constitutionally required supermajority in the lower house after allied parties withheld support, registering 259 votes for, 234 against and one abstention. The vote exposed a rare split in the governing coalition. Sheinbaum has proposed pursuing modifications to se…

National Presto Director Sells $347,975 in Stock Under 10b5-1 Plan

National Presto Director Sells $347,975 in Stock Under 10b5-1 Plan

National Presto Industries director Randy F. Lieble sold 2,417 shares of the company's common stock on March 11, 2026 at $143.97 per share, bringing the total transaction value to $347,975. The trade was carried out under a Rule 10b5-1 trading plan adopted November 10, 2025. Following the sale, Lieble holds 5,222 shares directly and additionally ha…

Lam Research: Why the Risk-Reward Is Tilting in Favor of a Long

Lam Research: Why the Risk-Reward Is Tilting in Favor of a Long

Lam Research has beaten recent estimates, guided higher, and sits squarely in the AI-driven capital expenditure cycle. Balance-sheet strength, robust free cash flow, and visible demand from memory and logic customers support a constructive long trade. Valuation is rich but not without justification given margins and cash generation; manage position…